Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ACUTE

stage 1 (T1, N0, M0)

1st line – radiotherapy

Back
ACUTE
|
stage 1 (T1, N0, M0)
1st line – 

radiotherapy

Radiotherapy without concurrent chemotherapy is the recommended treatment for patients with stage 1 disease.[2][19]​​​​​ In patients with clinically and radiographically undetectable nodal metastases (N0), reducing the nodal elective radiotherapy target volume to exclude level IV (low neck) can be considered.[30] 

Radiotherapy is the mainstay of treatment for non-metastatic nasopharyngeal cancer (NPC) given that it is a radiosensitive tumour and typically in a location that limits complete surgical resection.[1][2]​​​​​[19] The goal of treatment is cure for patients with non-metastatic NPC.[2] 

Conformal external beam radiotherapy (EBRT) techniques, including intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy, are considered the standard of care.[1][2]​​

stage 2 (T2, N0, M0)

1st line – radiotherapy

Back
ACUTE
|
stage 2 (T2, N0, M0)
1st line – 

radiotherapy

Radiotherapy is the recommended treatment for patients with low-risk stage 2 disease (N0 and pre-treatment plasma Epstein-Barr virus DNA <4000 copies/mL).[1][19]​​​​ In patients with clinically and radiographically undetectable nodal metastases (N0), reducing the nodal elective radiotherapy target volume to exclude level IV (low neck) can be considered.[1][30]​​​

Radiotherapy is the mainstay of treatment for non-metastatic nasopharyngeal cancer (NPC) given that it is a radiosensitive tumour and typically in a location that limits complete surgical resection.[1][2]​​​[19] The goal of treatment is cure for patients with non-metastatic NPC.[2] 

Conformal external beam radiotherapy (EBRT) techniques, including intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy, are considered the standard of care.[1][2]​​

Consider – chemotherapy

Back
ACUTE
|
stage 2 (T2, N0, M0)
Consider – 

chemotherapy

Additional treatment recommended for SOME patients in selected patient group

Use concurrent chemotherapy if high-risk features are present (such as bulky tumour volumes or high EBV DNA copy number).[1][19]​​

Cisplatin should be considered as the standard concurrent chemotherapy agent.[1][2]​​​​[19] For patients who cannot tolerate cisplatin (e.g., if there is pre-existing chronic kidney disease or hearing impairment), carboplatin is a reasonable alternative.[1][19]

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

Secondary options

carboplatin

stage 2 (T0 (EBV+)-T2, N1, M0)

1st line – chemoradiation

Back
ACUTE
|
stage 2 (T0 (EBV+)-T2, N1, M0)
1st line – 

chemoradiation

National Comprehensive Cancer Network (NCCN) guidelines recommend concurrent chemotherapy and radiotherapy.[19]

Radiotherapy is the mainstay of treatment for non-metastatic nasopharyngeal cancer (NPC) given that it is a radiosensitive tumour and typically in a location that limits complete surgical resection.[1][2]​​​[19] The goal of treatment is cure for patients with non-metastatic NPC.[2]

Conformal external beam radiotherapy (EBRT) techniques, including intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy, are considered the standard of care.[1][2]​​

Cisplatin should be considered as the standard concurrent chemotherapy agent.[1][2]​​​​[19] For patients who cannot tolerate cisplatin (e.g., if there is pre-existing chronic kidney disease or hearing impairment), carboplatin is a reasonable alternative.[1][19]​ Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information. 

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

Secondary options

carboplatin

Consider – i​nduction or adjuvant chemotherapy

Back
ACUTE
|
stage 2 (T0 (EBV+)-T2, N1, M0)
Consider – 

i​nduction or adjuvant chemotherapy

Additional treatment recommended for SOME patients in selected patient group

​The addition of induction chemotherapy (prior to the radiaotherapy) or of adjuvant chemotherapy is generally not recommended but could be considered after multidisciplinary discussion in select patients with large tumour burden or very high pre-treatment Epstein-Barr virus DNA copy number.[1][19]​​

Preferred induction regimens include gemcitabine plus cisplatin, or docetaxel plus cisplatin plus fluorouracil. Preferred adjuvant regimens include cisplatin (or carboplatin if cisplatin ineligible or intolerant) plus fluorouracil.[19] 

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

Induction regimen

gemcitabine

and

cisplatin

OR

Induction regimen

docetaxel

and

cisplatin

and

fluorouracil

OR

Adjuvant regimen

cisplatin

or

carboplatin

-- AND --

fluorouracil

stage 3 (T3, N0, M0)

1st line – chemoradiation

Back
ACUTE
|
stage 3 (T3, N0, M0)
1st line – 

chemoradiation

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer (NPC).[2]

Use radiotherapy plus concurrent chemotherapy for patients with stage 3 (T3, N0, M0) disease.[1][2][19]

Cisplatin should be considered as the standard concurrent chemotherapy agent.[1][2]​[19]​​​ For patients who cannot tolerate cisplatin (e.g., if there is pre-existing chronic kidney disease or hearing impairment), carboplatin is a reasonable alternative.[1][19]

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

Secondary options

carboplatin

Consider – induction or adjuvant chemotherapy

Back
ACUTE
|
stage 3 (T3, N0, M0)
Consider – 

induction or adjuvant chemotherapy

Additional treatment recommended for SOME patients in selected patient group

The addition of induction chemotherapy (prior to the radiotherapy) or of adjuvant chemotherapy to chemoradiation is generally not recommended for these patients with a more extensive primary tumour without nodal metastases, but could be considered after multidisciplinary discussion in select patients with large tumour burden or very high pre-treatment EBV DNA levels.[19]

Preferred induction regimens include gemcitabine plus cisplatin, or docetaxel plus cisplatin plus fluorouracil. Preferred adjuvant regimens include cisplatin (or carboplatin if cisplatin ineligible or intolerant) plus fluorouracil.[19]

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

Induction regimen

gemcitabine

and

cisplatin

OR

Induction regimen

docetaxel

and

cisplatin

and

fluorouracil

OR

Adjuvant regimen

cisplatin

or

carboplatin

-- AND --

fluorouracil

stage 3-4A (T3, N1-3, M0; OR T4, N0-3, M0; OR T0 (EBV+)-2, N2-3, M0)

1st line – induction chemotherapy + chemoradiation

Back
ACUTE
|
stage 3-4A (T3, N1-3, M0; OR T4, N0-3, M0; OR T0 (EBV+)-2, N2-3, M0)
1st line – 

induction chemotherapy + chemoradiation

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer (NPC).[2]

Induction chemotherapy is recommended for the majority of patients with stage 3-4A NPC (excluding T3, N0, M0).[1][19]​​​ Gemcitabine plus cisplatin, or docetaxel plus cisplatin plus fluorouracil are the preferred induction regimens.[1][19]​​​[34]

Concurrent chemoradiation is recommended for the majority of patients.[1][19]​​

Cisplatin should be considered as the standard concurrent chemotherapy agent.[1][2]​​​​[19] For patients who cannot tolerate cisplatin (e.g., if there is pre-existing chronic kidney disease or hearing impairment), carboplatin is a reasonable alternative.[1][19]

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

Induction regimen

gemcitabine

and

cisplatin

OR

Induction regimen

docetaxel

and

cisplatin

and

fluorouracil

OR

Concurrent chemoradiation regimen

cisplatin

OR

Concurrent chemoradiation regimen

carboplatin

Consider – clinical trial

Back
ACUTE
|
stage 3-4A (T3, N1-3, M0; OR T4, N0-3, M0; OR T0 (EBV+)-2, N2-3, M0)
Consider – 

clinical trial

Additional treatment recommended for SOME patients in selected patient group

Stage 3-4A (excluding T3, N0, M0) nasopharyngeal cancer is a particularly heterogeneous category. As such, participation in clinical trials is especially encouraged to better select subgroups of patients for more intensive treatments and other subgroups for less intensive treatments.[19]

2nd line – chemoradiation + adjuvant chemotherapy

Back
ACUTE
|
stage 3-4A (T3, N1-3, M0; OR T4, N0-3, M0; OR T0 (EBV+)-2, N2-3, M0)
2nd line – 

chemoradiation + adjuvant chemotherapy

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer.[2]

For patients who are ineligible for induction chemotherapy, adjuvant chemotherapy (cisplatin plus fluorouracil) is recommended after completion of concurrent chemoradiation.[1][19]​​ Cisplatin should be considered as the standard concurrent chemotherapy agent.[1][2]​​​​[19] For patients who cannot tolerate cisplatin (e.g., if there is pre-existing chronic kidney disease or hearing impairment), carboplatin is a reasonable alternative.[1][19]

Recommended chemotherapy regimens are based on NCCN guidelines and are preferred regimens.[19]​ Other alternative regimens are also recommended and you should consult your local guidelines for more information.

See local specialist protocol for dosing guidelines.

Primary options

Concurrent chemoradiation regimen

cisplatin

OR

Concurrent chemoradiation regimen

carboplatin

OR

Adjuvant regimen

cisplatin

or

carboplatin

-- AND --

fluorouracil

Consider – clinical trial

Back
ACUTE
|
stage 3-4A (T3, N1-3, M0; OR T4, N0-3, M0; OR T0 (EBV+)-2, N2-3, M0)
Consider – 

clinical trial

Additional treatment recommended for SOME patients in selected patient group

Stage 3-4A (excluding T3, N0, M0) nasopharyngeal cancer is a particularly heterogeneous category. As such, participation in clinical trials is especially encouraged to better select subgroups of patients for more intensive treatments and other subgroups for less intensive treatments.[19]

metastatic disease

1st line – chemotherapy + supportive care

Back
ACUTE
|
metastatic disease
1st line – 

chemotherapy + supportive care

​Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer (NPC).[2]

The preferred first-line treatment for patients with metastatic NPC who have no surgery or radiotherapy options is toripalimab (a programmed cell death protein 1 [PD-1] inhibitor) plus cisplatin plus gemcitabine.[19]

Other recommended first-line options include: cisplatin plus gemcitabine; cisplatin plus gemcitabine plus tislelizumab; cisplatin plus gemcitabine plus pembrolizumab or nivolumab; cisplatin plus fluorouracil; cisplatin or carboplatin plus docetaxel or paclitaxel; carboplatin plus cetuximab; and gemcitabine plus carboplatin.[19]

See local specialist protocol for dosing guidelines.

Supportive care can include speech and swallowing therapy, nutritional support, and psychosocial support. Provide pain management and consider how to control any bleeding.

Primary options

toripalimab

and

cisplatin

and

gemcitabine

OR

cisplatin

and

gemcitabine

OR

cisplatin

and

gemcitabine

and

tislelizumab

OR

cisplatin

and

gemcitabine

-- AND --

pembrolizumab

or

nivolumab

OR

cisplatin

and

fluorouracil

OR

cisplatin

or

carboplatin

-- AND --

docetaxel

or

paclitaxel

OR

carboplatin

and

cetuximab

OR

gemcitabine

and

carboplatin

ONGOING

locoregional nasopharyngeal and/or neck nodal recurrence

1st line – surgery ± adjuvant radiotherapy or chemoradiation

Back
ONGOING
|
locoregional nasopharyngeal and/or neck nodal recurrence
1st line – 

surgery ± adjuvant radiotherapy or chemoradiation

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer (NPC).[2]

Salvage nasopharyngectomy and/or neck dissection should be considered for small locoregional recurrences amenable for surgical resection.[2] Radical, modified radical, or selective neck dissection can be used for nodal neck recurrence.[2] The NCCN classifies cervical lymphadenectomy as either comprehensive or selective.[19]

Adjuvant radiation or chemoradiation is frequently offered after salvage surgery. There are limited data supporting the practice, but re-radiotherapy after salvage surgery is supported by consensus guidelines.[36]

Cisplatin or carboplatin plus paclitaxel is an example of a regimen that may be considered for chemoradiation.[19]​ However, chemotherapy for recurrences is highly specialized and local protocols should be followed for choice of regimen.

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

or

carboplatin

-- AND --

paclitaxel

2nd line – re-radiotherapy ± induction chemotherapy

Back
ONGOING
|
locoregional nasopharyngeal and/or neck nodal recurrence
2nd line – 

re-radiotherapy ± induction chemotherapy

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer.[2]

For unresectable locoregional recurrence, consider re-radiotherapy before a chemotherapy-only approach. Re-radiotherapy is challenging since many organs at risk have already been exposed to near maximal safe doses of radiation from the first course of radiotherapy and careful patient selection is needed.[2] International recommendations generally favour re-radiotherapy after at least 12 months latency between courses of radiotherapy to allow normal tissues to recover from the initial course of radiotherapy.[36] Unlike the first course of radiotherapy that includes targeting subclinical disease, re-radiotherapy targets gross recurrent tumour only.

Intensity-modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) is viewed as an appropriate modality for re-radiotherapy though if particle therapy such as proton therapy is available, it could be considered as well and may be preferred for select recurrences.[36]

For bulky recurrences, induction with concurrent chemotherapy is favoured among experts with re-radiotherapy.

Cisplatin or carboplatin plus gemcitabine is an example of a regimen that may be considered (if not received in the previous 6 months).[19]​ However, chemotherapy for recurrences is highly specialized and local protocols should be followed for choice of regimen.

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

or

carboplatin

-- AND --

gemcitabine

Plus – chemotherapy

Back
ONGOING
|
locoregional nasopharyngeal and/or neck nodal recurrence
Plus – 

chemotherapy

Treatment recommended for ALL patients in selected patient group

Chemotherapy is typically offered with concurrent re-irradiation.

Cisplatin plus fluorouracil is an example of a regimen that may be considered (if not received within the previous 6 months).[19]​ However, chemotherapy for recurrences is highly specialised and local protocols should be followed for choice of regimen.

See local specialist protocol for dosing guidelines.

Primary options

cisplatin

and

fluorouracil

3rd line – palliative chemotherapy + supportive care

Back
ONGOING
|
locoregional nasopharyngeal and/or neck nodal recurrence
3rd line – 

palliative chemotherapy + supportive care

Discuss the treatment strategy with the multidisciplinary team for patients with advanced nasopharyngeal cancer (NPC).[2]

Locoregional recurrence not amenable for salvage surgery or re-radiotherapy is treated with palliative chemotherapy. Palliative chemotherapy is highly specialised and local protocols should be followed for choice of agent.

Toripalimab (a programmed cell death protein 1 [PD-1] inhibitor) plus cisplatin plus gemcitabine is recommended as first-line option for patients with recurrent NPC who have no surgery or radiotherapy options.[19]

Other recommended first-line options include: cisplatin plus gemcitabine; cisplatin plus gemcitabine plus tislelizumab; cisplatin plus gemcitabine plus pembrolizumab or nivolumab; cisplatin plus fluorouracil; cisplatin or carboplatin plus docetaxel or paclitaxel; carboplatin plus cetuximab; and gemcitabine plus carboplatin.[19]

See local specialist protocol for dosing guidelines.

Supportive care can include speech and swallowing therapy, nutritional support, and psychosocial support. Provide pain management and consider how to control any bleeding.

Primary options

toripalimab

and

cisplatin

and

gemcitabine

OR

cisplatin

and

gemcitabine

OR

cisplatin

and

gemcitabine

and

tislelizumab

OR

cisplatin

and

gemcitabine

-- AND --

pembrolizumab

or

nivolumab

OR

cisplatin

and

fluorouracil

OR

cisplatin

or

carboplatin

-- AND --

docetaxel

or

paclitaxel

OR

carboplatin

and

cetuximab

OR

gemcitabine

and

carboplatin

back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer